| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 1g |
|
| ln Vitro |
When coupled with the Mycobacterium abscessus enzyme (PodA), tobramycin (0–50 ng/mL; 24 hours) dramatically lowers M. viability of aeruginosa cells [2].
|
|---|---|
| ln Vivo |
In a mouse pneumonia model, tobramycin (50–400 mg/kg/day, intraperitoneal injection, every 4 hours) can kill germs at low doses [3].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Pseudomonas aeruginosa Tested Concentrations: 2,10,50 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Cells compared to no protein or inactive Mycobacterium fortuitum enzyme (PodA) control Viability was greatly diminished, whereas PodA10 alone did not increase cell death. |
| Animal Protocol |
Animal/Disease Models: Pseudomonas aeruginosa pneumonia mouse model female, Swiss-Webster mice [3]
Doses: 50, 100. , 150, 214, and 400 mg/kg/day Dosing: intraperitonealevery 4 hrs (hrs (hours)) Experimental Results: When tobramycin was used alone, at approximately 150 mg/kg/day, the response to wild-type bacteria was Close to maximum killing effect. When used in combination with meropenem, low doses of both drugs (60 and 50 mg/kg/day for meropenem and tobramycin, respectively) produced near-maximal effects (i.e., killing of bacterial cells). Animal/Disease Models: Mice, rats, cats, and dogs for toxicological evaluation [4] Doses: 7.5, 15, 30, 120, 441,969 mg/kg Route of Administration: subcutaneous injection, intravenous (iv) (iv)injection, intramuscularinjection Experimental Results: sc LD50 values for mice and rats were 441 and 969 mg/kg respectively. Within 1 hour of treatment, rats and mice died preceded by central nervous system depression. intravenous (iv) (iv)doses of 100 mg/kg produced a moderate, transient decrease in blood pr |
| References |
[1]. Tobramycin.
[2]. VanDrisse CM, et.al. Computationally designed pyocyanin demethylase acts synergistically with tobramycin to kill recalcitrant Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022012118. [3]. Louie A, et.al. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 2013 Jun;57(6):2788-92. [4]. Welles JS, et.al. Preclinical toxicology studies with tobramycin. Toxicol Appl Pharmacol. 1973 Jul;25(3):398-409. |
| Molecular Formula |
C18H37N5O9
|
|---|---|
| Molecular Weight |
467.51
|
| CAS # |
32986-56-4
|
| Related CAS # |
Tobramycin sulfate;49842-07-1
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O[C@@H]([C@@H]1O[C@@]([C@@H](C[C@@H]2O)N)([H])O[C@@H]2CN)[C@H]([C@@H](C[C@@H]1N)N)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~213.90 mM)
DMSO : ~2 mg/mL (~4.28 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (213.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1390 mL | 10.6950 mL | 21.3899 mL | |
| 5 mM | 0.4278 mL | 2.1390 mL | 4.2780 mL | |
| 10 mM | 0.2139 mL | 1.0695 mL | 2.1390 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
